mynth
← DATABASE
09/2020

ADVANCED INSTRUMENTS acquired by PATRICIA INDUSTRIES

UNITED STATES Life Sciences / Medical Devices / Diagnostic Equipment EV $500M–1.5bn

Context

Patricia Industries, backed by the industrial holding power of Investor AB, has finalized the acquisition of Advanced Instruments from Windjammer Capital. The strategic rationale for this transaction centers on a "resilience-driven" play, merging the target's undisputed leadership in the specialized osmolality testing market with the acquirer's long-term capital and healthcare sector expertise. This fusion effectively secures a high-margin, capital-light platform that benefits from non-discretionary demand across clinical and biopharmaceutical end markets. This operation allows the organization to execute a definitive structural expansion into the high-growth cell and gene therapy sectors, where the target's instrumentation is a mission-critical component of complex biologics production. By incorporating the target's innovative technology and deep customer relationships into its global industrial network, the organization can now provide more robust and integrated solutions for pharmaceutical quality control. The maneuver optimizes the group's portfolio by adding a business characterized by high recurring revenue and strong cash conversion. Ultimately, the partnership solidifies the group's standing as a primary enabler of analytical precision, bridging the gap between clinical diagnostic excellence and industrialized biopharmaceutical manufacturing standards.

ADVANCED INSTRUMENTS, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of Above 20x, representing a premium to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Advanced Instruments operates as a premier technology organization dedicated to the engineering and distribution of specialized analytical instrumentation for the clinical, biopharmaceutical, and food and beverage sectors. The entity’s business model is centered on a proprietary framework of osmolality testing, providing critical diagnostic and quality control solutions for complex biologics and clinical diagnostics. Its value proposition is anchored in technical operational depth, serving as the global standard for fluid particle measurement in medical and industrial settings. Strategically, the firm focuses on the high-growth biopharmaceutical market, particularly within cell and gene therapy applications, while maintaining a resilient core in hospital diagnostics. By maintaining a specialized focus on technical excellence and customer-centricity, the organization ensures a mission-critical role in the structural efficiency of laboratory workflows and pharmaceutical production. The entity prioritizes technical innovation and industrialized precision to facilitate the structural advancement of patient diagnostics and product quality standards.

Ent. Value

$500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

Above 6x

EV / EBITDA

Above 20x

EV / EBIT

[members only]

Historical Financials (USD)

Year
Rev
EBITDA
EBIT
2019
$50–100M
$25–50M
[members only]
2018
$50–100M
$25–50M
[members only]

Similar deals in Life Sciences

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
DateAcquirerTargetCountrySector
10/2020ARDIANH2 PHARMAFRANCECDMO
10/2020SULZERHASELMEIERSWITZERLANDMedical Consumables
09/2020EQT PARTNERSSCHÜLKEGERMANYMedical Consumables
09/2020PERMIRANEURAXPHARMGERMANYGenerics / Labs
06/2020AVISTA CAPITAL PARTNERSVISION HEALTHCAREBELGIUMNutrition & Dietary Supplements
04/2020AMERICAN SECURITIESPARAGON MEDICALUNITED STATESMedical Devices
04/2020WARBURG PINCUSPOLYPLUSFRANCER&D Biotech
04/2020ROYAL DSMGLYCOMDENMARKNutrition & Dietary Supplements
03/2020LBO FRANCEDUTSCHERFRANCEMedical Consumables
02/2020PERRIGO COMPANYHIGH RIDGE BRANDS (ORAL CARE PORTFOLIO)UNITED STATESGenerics / Labs

REFERENCES

Valuation range: EV $500M–1.5bn

Revenue range: $50–100M

EBITDA range: $25–50M

EV/Revenue range: Above 6x

EV/EBITDA range: Above 20x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ADVANCED INSTRUMENTS by PATRICIA INDUSTRIES are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: patricia industries